NCT02599363: A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

NCT02599363
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: Rb+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Tumor must have Retinoblastoma protein positivity (Rb+)
Exclusions: Patient has known active CNS metastases, but can participate if they are clinically stable
https://ClinicalTrials.gov/show/NCT02599363

Comments are closed.

Up ↑